Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Corrigendum to 'Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs' [European Journal of Pharmaceutical Sciences 115 (2018) 175-184].

Notenboom S, Weigand KM, Proost JH, van Lipzig MM, van de Steeg E, van den Broek PHH, Greupink R, Russel FGM, Groothuis GMM.

Eur J Pharm Sci. 2018 May 30;117:392-393. doi: 10.1016/j.ejps.2018.04.005. No abstract available.

PMID:
29650218
2.

Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.

Notenboom S, Weigand KM, Proost JH, van Lipzig MMH, van de Steeg E, van den Broek PHH, Greupink R, Russel FGM, Groothuis GMM.

Eur J Pharm Sci. 2018 Mar 30;115:175-184. doi: 10.1016/j.ejps.2018.01.007. Epub 2018 Jan 5. Erratum in: Eur J Pharm Sci. 2018 May 30;117:392-393.

3.

Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?

Taneja A, Vermeulen A, Huntjens DRH, Danhof M, De Lange ECM, Proost JH.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.364.

4.

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach.

Yamamoto Y, Välitalo PA, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, Kokki H, Kokki M, Danhof M, van Hasselt JGC, de Lange ECM.

Eur J Pharm Sci. 2018 Jan 15;112:168-179. doi: 10.1016/j.ejps.2017.11.011. Epub 2017 Nov 11.

PMID:
29133240
5.

Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model.

Yamamoto Y, Välitalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, van den Berg DJ, Hartman R, Wong YC, Danhof M, van Hasselt JGC, de Lange ECM.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):765-777. doi: 10.1002/psp4.12250. Epub 2017 Oct 13.

6.

Combined proportional and additive residual error models in population pharmacokinetic modelling.

Proost JH.

Eur J Pharm Sci. 2017 Nov 15;109S:S78-S82. doi: 10.1016/j.ejps.2017.05.021. Epub 2017 May 13.

7.

An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics.

Eleveld DJ, Proost JH, Vereecke H, Absalom AR, Olofsen E, Vuyk J, Struys MMRF.

Anesthesiology. 2017 Jun;126(6):1005-1018. doi: 10.1097/ALN.0000000000001634.

PMID:
28509794
8.

Pharmacokinetic modeling of gentamicin in treatment of infective endocarditis: Model development and validation of existing models.

Gomes A, van der Wijk L, Proost JH, Sinha B, Touw DJ.

PLoS One. 2017 May 5;12(5):e0177324. doi: 10.1371/journal.pone.0177324. eCollection 2017.

9.

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.

10.

Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration.

van den Berg JP, Vereecke HE, Proost JH, Eleveld DJ, Wietasch JK, Absalom AR, Struys MM.

Br J Anaesth. 2017 Jan;118(1):44-57. doi: 10.1093/bja/aew312.

12.

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.

Yamamoto Y, Välitalo PA, van den Berg DJ, Hartman R, van den Brink W, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Bakshi S, Aranzana-Climent V, Marchand S, Dahyot-Fizelier C, Couet W, Danhof M, van Hasselt JG, de Lange EC.

Pharm Res. 2017 Feb;34(2):333-351. doi: 10.1007/s11095-016-2065-3. Epub 2016 Nov 18.

13.

Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats.

Taneja A, Vermeulen A, Huntjens DR, Danhof M, De Lange EC, Proost JH.

Data Brief. 2016 Aug 6;8:1433-7. doi: 10.1016/j.dib.2016.07.060. eCollection 2016 Sep.

14.

A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.

Taneja A, Vermeulen A, Huntjens DRH, Danhof M, De Lange ECM, Proost JH.

Eur J Pharmacol. 2016 Oct 15;789:202-214. doi: 10.1016/j.ejphar.2016.07.005. Epub 2016 Jul 6.

PMID:
27395799
15.

Probability to tolerate laryngoscopy and noxious stimulation response index as general indicators of the anaesthetic potency of sevoflurane, propofol, and remifentanil.

Hannivoort LN, Vereecke HE, Proost JH, Heyse BE, Eleveld DJ, Bouillon TW, Struys MM, Luginbühl M.

Br J Anaesth. 2016 May;116(5):624-31. doi: 10.1093/bja/aew060.

16.

A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.

Heetla HW, Proost JH, Molmans BH, Staal MJ, van Laar T.

Br J Clin Pharmacol. 2016 Jan;81(1):101-12.

17.

Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 May;33(5):1305-6. doi: 10.1007/s11095-016-1888-2. Epub 2016 Mar 10. No abstract available.

18.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 Apr;33(4):1003-17. doi: 10.1007/s11095-015-1846-4. Epub 2015 Dec 30. Erratum in: Pharm Res. 2016 May;33(5):1305-6.

PMID:
26718955
19.

Pharmacokinetics of clomipramine during pregnancy.

Ter Horst PG, Proost JH, Smit JP, Vries MT, de Jong-van de Berg LT, Wilffert B.

Eur J Clin Pharmacol. 2015 Dec;71(12):1493-500. doi: 10.1007/s00228-015-1944-6. Epub 2015 Sep 29.

PMID:
26416100
20.

Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.

Boer H, Proost JH, Nuver J, Bunskoek S, Gietema JQ, Geubels BM, Altena R, Zwart N, Oosting SF, Vonk JM, Lefrandt JD, Uges DR, Meijer C, de Vries EG, Gietema JA.

Ann Oncol. 2015 Nov;26(11):2305-10. doi: 10.1093/annonc/mdv369. Epub 2015 Sep 7.

21.

Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.

Dijkstra JA, van Altena R, Akkerman OW, de Lange WC, Proost JH, van der Werf TS, Kosterink JG, Alffenaar JW.

Int J Antimicrob Agents. 2015 Sep;46(3):332-7. doi: 10.1016/j.ijantimicag.2015.06.008. Epub 2015 Jul 15.

PMID:
26228464
22.

Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers.

Hannivoort LN, Eleveld DJ, Proost JH, Reyntjens KM, Absalom AR, Vereecke HE, Struys MM.

Anesthesiology. 2015 Aug;123(2):357-67. doi: 10.1097/ALN.0000000000000740.

PMID:
26068206
23.

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.

24.

In response.

Eleveld DJ, Proost JH, Absalom AR, Cortínez LI, Struys MM.

Anesth Analg. 2015 Mar;120(3):693-4. doi: 10.1213/ANE.0000000000000579. No abstract available.

PMID:
25695587
25.

Limited-sampling strategies for anidulafungin in critically ill patients.

van Wanrooy MJ, Proost JH, Rodgers MG, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Feb;59(2):1177-81. doi: 10.1128/AAC.03375-14. Epub 2014 Dec 8.

26.

Clonidine as an adjuvant to prolong local analgesia in conventional scleral buckle surgery.

Górniak M, Proost JH, Veckeneer M, Mulder VC, Wubbels RJ.

J Ocul Pharmacol Ther. 2014 Nov;30(9):777-82. doi: 10.1089/jop.2013.0243. Epub 2014 Sep 4.

PMID:
25188774
27.

Clinical relevance of pharmacological and physiological data in intrathecal baclofen therapy.

Heetla HW, Staal MJ, Proost JH, van Laar T.

Arch Phys Med Rehabil. 2014 Nov;95(11):2199-206. doi: 10.1016/j.apmr.2014.04.030. Epub 2014 Jun 2. Review.

PMID:
24893275
28.

Sex differences in the pharmacokinetics of antidepressants: influence of female sex hormones and oral contraceptives.

Damoiseaux VA, Proost JH, Jiawan VC, Melgert BN.

Clin Pharmacokinet. 2014 Jun;53(6):509-19. doi: 10.1007/s40262-014-0145-2. Review.

PMID:
24859034
29.

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2014 Oct;31(10):2605-17. doi: 10.1007/s11095-014-1358-7. Epub 2014 May 3.

PMID:
24792824
30.

A general purpose pharmacokinetic model for propofol.

Eleveld DJ, Proost JH, Cortínez LI, Absalom AR, Struys MM.

Anesth Analg. 2014 Jun;118(6):1221-37. doi: 10.1213/ANE.0000000000000165.

PMID:
24722258
31.

A response surface model approach for continuous measures of hypnotic and analgesic effect during sevoflurane-remifentanil interaction: quantifying the pharmacodynamic shift evoked by stimulation.

Heyse B, Proost JH, Hannivoort LN, Eleveld DJ, Luginbühl M, Struys MM, Vereecke HE.

Anesthesiology. 2014 Jun;120(6):1390-9. doi: 10.1097/ALN.0000000000000180.

PMID:
24566244
32.

Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.

Pilla Reddy V, Kozielska M, Johnson M, Mafirakureva N, Vermeulen A, Liu J, de Greef R, Rujescu D, Groothuis GM, Danhof M, Proost JH.

J Clin Psychopharmacol. 2013 Dec;33(6):731-9. doi: 10.1097/JCP.0b013e3182a4ee2c.

PMID:
24113674
33.

Renal function assessment in older adults.

Drenth-van Maanen AC, Jansen PA, Proost JH, Egberts TC, van Zuilen AD, van der Stap D, van Marum RJ.

Br J Clin Pharmacol. 2013 Oct;76(4):616-23. doi: 10.1111/bcp.12199.

34.

Nanoparticle formulation of a poorly soluble cannabinoid receptor 1 antagonist improves absorption by rat and human intestine.

Siissalo S, de Waard H, de Jager MH, Hayeshi R, Frijlink HW, Hinrichs WL, Dinter-Heidorn H, van Dam A, Proost JH, Groothuis GM, de Graaf IA.

Drug Metab Dispos. 2013 Aug;41(8):1557-65. doi: 10.1124/dmd.112.049585. Epub 2013 Jun 3.

35.

Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.

Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH.

Schizophr Res. 2013 May;146(1-3):153-61. doi: 10.1016/j.schres.2013.02.010. Epub 2013 Mar 6.

36.

Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.

Pilla Reddy V, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH.

Schizophr Res. 2013 May;146(1-3):144-52. doi: 10.1016/j.schres.2013.02.011. Epub 2013 Mar 6.

37.

Bilitranslocase is involved in the uptake of bromosulfophthalein in rat and human liver.

Terdoslavich M, de Graaf IA, Proost JH, Cocolo A, Passamonti S, Groothuis GM.

Drug Metab Lett. 2012 Sep 1;6(3):165-73.

PMID:
23470127
38.

Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.

Kozielska M, Pilla Reddy V, Johnson M, de Ridder F, Vermeulen A, Liu J, Groothuis GM, Danhof M, Proost JH.

Schizophr Res. 2013 May;146(1-3):53-8. doi: 10.1016/j.schres.2013.01.022. Epub 2013 Feb 20.

PMID:
23434198
39.

Interaction between nitrous oxide, sevoflurane, and opioids: a response surface approach.

Vereecke HE, Proost JH, Heyse B, Eleveld DJ, Katoh T, Luginbühl M, Struys MM.

Anesthesiology. 2013 Apr;118(4):894-902. doi: 10.1097/ALN.0b013e3182860486.

PMID:
23360899
40.

Modelling and simulation of placebo effect: application to drug development in schizophrenia.

Pilla Reddy V, Kozielska M, de Greef R, Vermeulen A, Proost JH.

J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):377-88. doi: 10.1007/s10928-012-9296-7. Epub 2013 Jan 12. Review.

PMID:
23315146
41.

Influence of erroneous patient records on population pharmacokinetic modeling and individual bayesian estimation.

van der Meer AF, Touw DJ, Marcus MA, Neef C, Proost JH.

Ther Drug Monit. 2012 Oct;34(5):526-34. doi: 10.1097/FTD.0b013e3182616937.

PMID:
22846895
42.

Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2012 Jul;29(7):1932-48. doi: 10.1007/s11095-012-0722-8. Epub 2012 Mar 22.

43.

Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Pilla Reddy V, Kozielska M, Johnson M, Suleiman AA, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH.

Clin Pharmacokinet. 2012 Apr 1;51(4):261-75. doi: 10.2165/11598460-000000000-00000.

PMID:
22420580
44.

Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

van Kuilenburg AB, Häusler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, Behnke D, Schwabe W, Jabschinsky K, Maring JG.

Clin Pharmacokinet. 2012 Mar 1;51(3):163-74. doi: 10.2165/11595880-000000000-00000.

PMID:
22339448
45.

Sevoflurane remifentanil interaction: comparison of different response surface models.

Heyse B, Proost JH, Schumacher PM, Bouillon TW, Vereecke HE, Eleveld DJ, Luginbühl M, Struys MM.

Anesthesiology. 2012 Feb;116(2):311-23. doi: 10.1097/ALN.0b013e318242a2ec.

PMID:
22222473
46.

Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements.

Pilla Reddy V, Petersson KJ, Suleiman AA, Vermeulen A, Proost JH, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1:e1. doi: 10.1038/psp.2012.9.

47.

Obesity and allometric scaling of pharmacokinetics.

Eleveld DJ, Proost JH, Absalom AR, Struys MM.

Clin Pharmacokinet. 2011 Nov 1;50(11):751-3; discussion 755-6. doi: 10.2165/11594080-000000000-00000. No abstract available.

PMID:
21973272
48.

PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.

Bansal R, Post E, Proost JH, de Jager-Krikken A, Poelstra K, Prakash J.

J Control Release. 2011 Sep 25;154(3):233-40. doi: 10.1016/j.jconrel.2011.05.027. Epub 2011 Jun 12.

PMID:
21664391
49.

Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH.

Clin Pharmacokinet. 2011 Jul;50(7):429-50. doi: 10.2165/11590590-000000000-00000.

PMID:
21651312
50.

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2011 Oct;28(10):2490-504. doi: 10.1007/s11095-011-0477-7. Epub 2011 Jun 7.

Supplemental Content

Loading ...
Support Center